January 2025
2024 has been a breakout year for EicOsis. From being recognized as one of Pepperdine University’s Most Fundable Companies to wrapping up successful Phase 1 trials for our groundbreaking leading compound, we are at the forefront of tackling pain without the risks of opioids. With growing investor interest in neuroinflammation and our trailblazing advances in sEH inhibition, we’re uniquely poised to redefine pain management and neuroinflammatory therapies.
Don’t miss this moment. Explore how we’re transforming science into solutions—and why now is the perfect time to join our journey.
In this newsletter:
- Our Industry: Investment in Pharma is booming
- Our Science: Understanding more of the potential for sEH inhibitors in collaboration with the best research institutions
- Our Progress: Tolerance, Pharmacokinetic, and safety details
- Our Finance: Runway and fundraising updates
